Emily Kimber's profile photo

Emily Kimber

United Kingdom

Deputy Editor at PMLiVE

Featured in: Favicon pmlive.com Favicon einnews.com Favicon pharmatimes.com Favicon biopharmadive.com

Articles

  • Patrick Daly - PharmaTimes

    2 days ago | pharmatimes.com | Emily Kimber

    Terumo BCT has appointed Patrick Daly as Chief Business Officer Terumo Blood and Cell Technologies (Terumo BCT) has announced the appointment of Patrick Daly as its Chief Business Officer. Daly joins the medical technology company with more than three decades of business and healthcare industry experience.

  • Genomics study launches to optimise childhood cancer care in Ireland

    2 days ago | pharmatimes.com | Emily Kimber

    It is hoped that the MAGIC-I study will support earlier diagnosis and personalised treatment A five-year clinical study aiming to optimise childhood cancer care in Ireland has been launched. MAGIC-I, or Molecular and Genomic Interrogation of Childhood Cancer – Ireland, is focused on better understanding how and why cancer develops, and why outcomes and side effects vary between patients.

  • Roche’s Genentech enters $765m autoimmune disease partnership with Repertoire

    2 days ago | pmlive.com | Emily Kimber

    Roche’s Genentech unit and Repertoire Immune Medicines have entered into a partnership worth $765m to discover and develop T cell-targeted immune medicines for an undisclosed autoimmune disease. The collaboration and licence agreement centres around Repertoire’s DECODE platform, which will be used to generate target discoveries that Genentech will further optimise and translate into new drugs.

  • Biogen’s Skyclarys granted MHRA approval for rare movement disorder Friedreich’s ataxia

    2 days ago | pmlive.com | Emily Kimber

    Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first treatment for patients aged 16 years and older with the rare neurodegenerative movement disorder Friedreich’s ataxia (FA). FA is the most common inherited ataxia, a group of disorders affecting coordination, balance and speech, affecting at least one in every 50,000 people in the UK.

  • Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    2 days ago | pmlive.com | Emily Kimber

    Gilead Sciences has shared positive top-line results from a late-stage study evaluating its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) with Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) in triple-negative breast cancer (TNBC) patients.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →